Value Stocks: 1 Cheap Healthcare Company for TFSA Investors

Theratechnologies Inc. (TSX:TH)(NASDAQ:THTX) is pursuing potential product acquisitions, in-licensing transactions, and other similar opportunities complementary to the company’s business.

| More on:
Test tubes

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Theratechnologies (TSX:TH)(NASDAQ:THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

The company’s business strategy is to grow revenues from Theratechnologies’s existing and future assets in North America and Europe and to develop a portfolio of complementary products that are compatible with the company’s expertise in drug development and commercialization know-how.

Regulatory approvals

Currently, the company has two approved products — namely, EGRIFTA and Trogarzo in the United States, the European Union, and the United Kingdom. EGRIFTA was originally approved by the U.S. Food and Drug Administration (FDA) in November 2010 and was launched in the United States in January 2011.

Exclusive marketing

EGRIFTA can be kept at room temperature, comes in a single vial, and has a higher concentration resulting in a smaller volume of administration. The drug is currently the only approved therapy in the United States for the reduction of excess abdominal fat in human immunodeficiency virus (HIV) infected patients. EGRIFTA is also approved by Health Canada and was launched in Canada in June 2015.

In Canada, EGRIFTA is the only approved drug for the treatment of excess visceral adipose tissue, as assessed by high waist circumference in adult HIV-infected patients. EGRIFTA is marketed exclusively by the company in Canada and Mexico’s health agency has also approved the drug.

Benefitting from early-access programs

The company’s Trogarzo injection was approved by the FDA in March 2018 and was made commercially available in the United States. Trogarzo is also commercially available in Germany and in other countries through early access programs.

Trogarzo is the first HIV treatment approved with a new mechanism of action in more than 10 years. The treatment is infused every two weeks. It is the first in a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs.

Promising pipeline of investigational medicines

In addition to the sale of company’s products, Theratechnologies is also conducting research and development activities. The company has a promising pipeline of investigational medicines in the areas of oncology. Tesamorelin, the active ingredient in EGRIFTA, is designed to increase endogenous growth hormone secretion. Tesamorelin has a well-established safety profile, with more than 10 years of product history.

Robust business strategy

The company plans on initiating a phase-three clinical trial to study tesamorelin for the treatment of various types of cancers. Theratechnologies’s business strategy is focused on increasing sales of EGRIFTA and Trogarzo in the United States. Further, the company plan to launch Trogarzo in key countries of the E.U. and obtain reimbursements for the product.

Potential product acquisitions

Further, the company is beginning a phase-one clinical trial using Theratechnologies’s products in various types of cancers in the second quarter of 2021. The company is pursuing potential product acquisitions, in-licensing transactions, or other similar opportunities that are complementary to the company’s business. The company is also managing its financial position to ensure it can successfully execute business objectives. This could lead to a significantly higher stock price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

growing plant shoots on stacked coins
Dividend Stocks

2 Oversold TSX Dividend Stocks to Buy Now and Own for 25 Years

These top TSX dividend stocks look oversold and now offer attractive yields for TFSA and RRSP investors.

Read more »

money cash dividends

Passive-Income Power: How to Make $105/Week TAX FREE in a Bear Market

Investors may want to pursue a passive-income strategy in this bear market by snagging dividend stocks like Freehold Royalties Ltd.…

Read more »

Money growing in soil , Business success concept.
Energy Stocks

3 Growth Stocks up +30% in 2022

These three growth stocks are up over 30% in 2022 alone but have come down in the last few weeks…

Read more »

Oil pumps against sunset
Energy Stocks

2 Energy Stocks That Jumped Over 60% This Year

Consider investing in these two energy stocks amid the recent pullback after putting up stellar gains earlier this year.

Read more »

Profit dial turned up to maximum
Dividend Stocks

RRSP Investors: 2 Undervalued TSX Stocks to Buy Now for Total Returns

Top TSX dividend stocks are now on sale for RRSP investors seeking attractive total returns.

Read more »

TFSA and coins
Dividend Stocks

2 Beaten-Down Stocks to Buy for Your TFSA

Two beaten-down, but high-yield TSX stocks are profitable options for TFSA investors.

Read more »

Volatile market, stock volatility
Stocks for Beginners

3 Top TSX Stocks to Buy in Volatile Markets

Sitting on cash? Consider these three TSX stocks for the long term.

Read more »

Hand writing Time for Action concept with red marker on transparent wipe board.
Dividend Stocks

Inflation Soars to 7.7%: 1 Dividend Stock to Buy Now

Enbridge (TSX:ENB)(NYSE:ENB) stock looks like a magnificent dividend stock to help Canadians deal with inflation at 7.7%.

Read more »